Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

  1. Muik, A.
  2. Garralda, E.
  3. Altintas, I.
  4. Gieseke, F.
  5. Geva, R.
  6. Ben-Ami, E.
  7. Maurice-Dror, C.
  8. Calvo, E.
  9. Lorusso, P.M.
  10. Alonso, G.
  11. Rodriguez-Ruiz, M.E.
  12. Schoedel, K.B.
  13. Blum, J.M.
  14. Sänger, B.
  15. Salcedo, T.W.
  16. Burm, S.M.
  17. Stanganello, E.
  18. Verzijl, D.
  19. Vascotto, F.
  20. Sette, A.
  21. Quinkhardt, J.
  22. Plantinga, T.S.
  23. Toker, A.
  24. Van Den Brink, E.N.
  25. Fereshteh, M.
  26. Diken, M.
  27. Satijn, D.
  28. Kreiter, S.
  29. Breij, E.C.W.
  30. Bajaj, G.
  31. Lagkadinou, E.
  32. Sasser, K.
  33. Türeci, Ö.
  34. Forssmann, U.
  35. Ahmadi, T.
  36. Şahin, U.
  37. Jure-Kunkel, M.
  38. Melero, I.
  39. Show all authors +
Journal:
Cancer Discovery

ISSN: 2159-8290,  2159-8274

Year of publication: 2022

Volume: 12

Issue: 5

Pages: 1248-1265

Type: Article

DOI: 10.1158/2159-8290.CD-21-1345 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus